|
|
 Previous Article | Table of Contents | Next Article 
Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors
Elizabeth Mansfield,
Peter Amlot,
Ira Pastan, and
David J. FitzGerald
From the Laboratory of Molecular Biology, DCBDC, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Department of Immunology, Royal Free Hospital, London, England.
Many B-cell malignancies express the CD22 antigen on their cell surface. To kill cells expressing this antigen, the RFB4 monoclonal antibody (MoAb) has been linked chemically with either deglycosylated ricin A chain or truncated versions of Pseudomonas exotoxin. These immunotoxins exhibited selective cytotoxic activity for CD22+ cells and antitumor activity in nude mouse models bearing human B-cell lymphomas. To construct a recombinant immunotoxin targeted to CD22, we first cloned the variable portions of the heavy and light chains of RFB4. The cloned Fv fragments were joined by a newly created disulfide bond to form a disulfide stabilized (ds) construct. The RFB4 construct was combined by gene fusion with PE38, a truncated version of PE. The recombinant immunotoxin was then expressed in Escherichia coli, purified by column chromatography and tested for cytotoxicity activity. RFB4(dsFv)PE38 retained its binding activity for CD22, was very stable at 37°C and exhibited selective cytotoxic activity for CD22+-cultured cell lines. Because of its favorable binding characteristics and potency for CD22-positive cell lines, RFB4(dsFv)PE38 was tested for antitumor activity in a nude mouse model of human lymphoma. CA46 cells were injected subcutaneously and then treated with the RFB4(dsFv)PE38 immunotoxin. Antitumor activity was dose responsive and was not evident when an irrelevant immunotoxin was administered on the same schedule.
Blood, Vol. 90 No. 5 (September 1), 1997:
pp. 2020-2026
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
X. Du, S. Nagata, T. Ise, M. Stetler-Stevenson, and I. Pastan
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
Blood,
January 1, 2008;
111(1):
338 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Varki and T. Angata
Siglecs--the major subfamily of I-type lectins
Glycobiology,
January 1, 2006;
16(1):
1R - 27R.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
J. Clin. Oncol.,
September 20, 2005;
23(27):
6719 - 6729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bang, S. Nagata, M. Onda, R. J. Kreitman, and I. Pastan
HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity
Clin. Cancer Res.,
February 15, 2005;
11(4):
1545 - 1550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ho, R. J. Kreitman, M. Onda, and I. Pastan
In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin
J. Biol. Chem.,
January 7, 2005;
280(1):
607 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ise, H. Maeda, K. Santora, L. Xiang, R. J. Kreitman, I. Pastan, and S. Nagata
Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies
Clin. Cancer Res.,
January 1, 2005;
11(1):
87 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang and A. Varki
Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis
Glycobiology,
November 1, 2004;
14(11):
939 - 949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, M. Oelsner, R. J. Kreitman, G. Salvatore, Q.-c. Wang, I. Pastan, C. Peschel, and T. Licht
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
Blood,
April 1, 2004;
103(7):
2718 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onda, Q.-c. Wang, H.-f. Guo, N.-K. V. Cheung, and I. Pastan
In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma
Cancer Res.,
February 15, 2004;
64(4):
1419 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Meng, J. E. Smallshaw, L. M. Pop, M. Yen, X. Liu, L. Le, M.-A. Ghetie, E. S. Vitetta, and V. Ghetie
The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies
Clin. Cancer Res.,
February 15, 2004;
10(4):
1274 - 1281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Krauss, M. A.E. Arndt, A. C.R. Martin, H. Liu, and S. M. Rybak
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment
Protein Eng. Des. Sel.,
October 1, 2003;
16(10):
753 - 759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
Ann. Onc.,
May 1, 2003;
14(5):
729 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. John, B. R. Herrin, C. Raman, Y.-n. Wang, K. R. Bobbitt, B. A. Brody, and L. B. Justement
The B Cell Coreceptor CD22 Associates with AP50, a Clathrin-Coated Pit Adapter Protein, Via Tyrosine-Dependent Interaction
J. Immunol.,
April 1, 2003;
170(7):
3534 - 3543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagata, M. Onda, Y. Numata, K. Santora, R. Beers, R. J. Kreitman, and I. Pastan
Novel Anti-CD30 Recombinant Immunotoxins Containing Disulfide-stabilized Fv Fragments
Clin. Cancer Res.,
July 1, 2002;
8(7):
2345 - 2355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schnell, O. Staak, P. Borchmann, C. Schwartz, B. Matthey, H. Hansen, J. Schindler, V. Ghetie, E. S. Vitetta, V. Diehl, et al.
A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
June 1, 2002;
8(6):
1779 - 1786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Salvatore, R. Beers, I. Margulies, R. J. Kreitman, and I. Pastan
Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display
Clin. Cancer Res.,
April 1, 2002;
8(4):
995 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, S. Hipp, R. J. Kreitman, I. Pastan, C. Peschel, and T. Licht
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
Blood,
February 15, 2002;
99(4):
1320 - 1326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Kreitman, I. Margulies, M. Stetler-Stevenson, Q.-C. Wang, D. J. P. FitzGerald, and I. Pastan
Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias
Clin. Cancer Res.,
April 1, 2000;
6(4):
1476 - 1487.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. L. Cornish, S. Freeman, G. Forbes, J. Ni, M. Zhang, M. Cepeda, R. Gentz, M. Augustus, K. C. Carter, and P. R. Crocker
Characterization of Siglec-5, a Novel Glycoprotein Expressed on Myeloid Cells Related to CD33
Blood,
September 15, 1998;
92(6):
2123 - 2132.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
